
    
      STUDY DESIGN:

        -  multicenter, phase III, double-blind, randomized entry of patients, prospective and
           comparative

        -  The duration of the study: 60 days

        -  3 visits (days 1, 30 and 60)

        -  Evaluate the effectiveness of the association

        -  Evaluate the safety of the combination

        -  Adverse events evaluation
    
  